sponsored
PatientsVille.com Logo

PatientsVille

Imuran Medical Research Studies

Up-to-date List of Imuran Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Imuran Medical Research Studies

Rank Status Study
1 Not yet recruiting Cimzia Versus Cimzia Plus Azathioprine in the Treatment of Active Crohn's Disease
Condition: Crohn's Disease
Interventions: Biological: Certolizumab pegol;   Drug: Azathioprine
Outcome Measures: Change in mean simple endoscopic scoring achieved by monotherapy versus combination therapy;   Assess differences in response rates and remission rates between the two groups
2 Recruiting Rituximab Vasculitis Maintenance Study
Conditions: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis;   Microscopic Polyangiitis;   Wegener Granulomatosis
Interventions: Biological: Rituximab;   Drug: Azathioprine
Outcome Measures: Time to relapse;   Remission at 24 and 48 months;   Combined damage assessment score;   Health-related quality of life;   Cumulative GC exposure;   Severe adverse event rate;   Infection rates
3 Recruiting Leflunomide Versus Azathioprine for Maintenance Therapy of Lupus Nephritis
Conditions: Nephritis;   Lupus
Interventions: Drug: Leflunomide;   Drug: Azathioprine
Outcome Measures: lupus nephritis flare;   24-hour proteinuria over time;   Serum albumin over time;   Number of extra renal flare;   Cumulated glucocorticoid intake
4 Unknown  Prevention of Relapses in Proteinase 3 (PR3)-Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis
Condition: Vasculitis
Intervention: Drug: azathioprine
Outcome Measures: disease free survival;   cumulative organ damage;   side-effects;   cumulative dosages of cyclophosphamide, prednisolone and azathioprine;   quality of life
5 Recruiting Belimumab in Remission of VASculitis
Condition: Vasculitis
Interventions: Biological: Placebo;   Biological: Belimumab 10 mg/kg;   Drug: Azathioprine
Outcome Measures: Time to first relapse;   Time to first major relapse;   Number of participants who experienced adverse events
6 Recruiting Enteric-coated Mycophenolate Sodium Versus Azathioprine for the Extra-renal Lupus Manifestations
Condition: Systemic Lupus Erythematosus
Interventions: Drug: Azathioprine;   Drug: Enteric-Coated Mycophenolate Sodium
Outcome Measures: Obtention of complete remission;   To evaluate the safety, improvement in biological parameters and reduction of number of extra-renal flares.
7 Unknown  Azathioprine and Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis
Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: Placebo;   Drug: AZAPRED
Outcome Measures: Progression-free survival, defined as free of death or a decrease from baseline in the FVC of at least 10%.;   Number of Acute Exacerbations of IPF.;   Health Related Quality of life, measured with the Chronic Questionnaire (CRQ).;   PO2 at rest and at exercise from baseline.;   P(A-a)O2 at rest and at exercise from baseline.;   Predicted FEV1 from baseline.;   Forced expiratory volume in one second (FEV1) to FVC from baseline.;   Plethysmographic lung volumes from baseline.;   Diffusion capacity for carbon monoxide (DLco) from baseline.;   Six-Minute Walk test, from baseline: resting and 6 minute SpO2, presence or absence of desaturation to 88% or lower at the end of the six minute walk, walked distance d. Pre and post modified Borg dyspnea scores;   Scoring of extent of lung fibrosis on HRCT, according to two independent chest radiologists, form baseline.;   Number and severity of adverse effects.;   Number of protocol drop outs.
8 Recruiting The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy
Condition: Myasthenia Gravis
Interventions: Drug: Azathioprine;   Drug: Leflunomide
Outcome Measures: the percent of achieving good response;   level of the AChR-Ab
9 Recruiting The Efficacy of Enteral Nutrition in Fill of the Treatment Blank Period of the Postoperative Maintain Remission Medication for Crohn's Disease (CD)
Condition: Crohn's Disease
Interventions: Drug: azathioprine+enteral nutrition;   Drug: Azathioprine
Outcome Measures: The change of patients'CDAI.;   patients' endoscopic score(Rutgeerts score).;   The change of haematological inflammation marker(CRP,ESR);   The change of patients'IBDQ.;   The change of blood routine examination and blood biochemistry.
10 Unknown  Biomarkers of Lupus Disease: Serial Biomarker Sampling in Patients With Active Systemic Lupus Erythematosus (SLE)
Condition: Systemic Lupus Erythematosus
Interventions: Drug: Depomedrol;   Other: Blood drawing only;   Drug: Methotrexate and depomedrol;   Drug: Mycophenolate mofetil and depomedrol
Outcome Measures: To determine major biomarker patterns in lupus patients flaring on minimal background medications and compare to those flaring on typical background meds used in clinic and clinical trials;   Biomarkers of steroid efficacy and toxicity;   validation of disease activity and flare instruments in development;   Patient reported outcomes and validation of new lupus specific quality of life and patient reported outcome measures
11 Recruiting Immune Response to Vaccination in Patients Receiving Single Drug Immunosuppression
Condition: Immunosuppression
Intervention: Biological: Flu Vaccine
Outcome Measures: Specific Aim 1: Characterize influenza antibody titers before and after vaccination in patients taking azathioprine, TNF-alpha, or in healthy controls.;   Specific Aim 2: Characterize the B cell responses to influenza vaccination in patients taking azathioprine, TNF-alpha, or in healthy controls.
12 Recruiting Efficacy Study of T2 Versus AZA to Maintain Clinical and Endoscopic Remission in Postoperative Crohn's Disease
Condition: Crohn's Disease
Interventions: Drug: T2;   Drug: Azathioprine
Outcome Measures: Clinical Remission: the proportion of patients with CDAI <150 at 26 and 52 weeks;   Endoscopic Remission: the proportion of patients with CDEIS <6 at 26 and 52 weeks;   The time till the clinical relapse of CD(the CDAI >150 or an increase of more than 70 points);   The time till the histological recurrence(determined by biopsies and endoscopic findings);   Serum C-reactive protein concentration; Erythrocyte Sedimentation Rate;   The proportion of patients experiencing adverse events
13 Recruiting CZECH-ICIT (CZECH Inflammatory Cardiomyopathy Immunosuppression Trial)
Condition: Inflammatory Cardiomyopathy
Interventions: Drug: Combination of prednisone and azathioprine;   Other: No intervention
Outcome Measures: comparison of the change in LV ejection fraction;   comparison of the change of LV end-diastolic and end-systolic diameters;   comparison of the change of New York Heart Association (NYHA) class;   comparison of total mortality;   comparison of the combined end-point;   comparison of the change in the number of infiltrating inflammatory cells in EMB
14 Recruiting Comparison of 2 Immunomodulator Withdrawal Schemes for Inflixiamb Monotherapy in Active Pediatric Crohn's Disease After Thiopurine Failure
Condition: Crohn's Disease
Intervention: Drug: AZATHIOPRINE or METHOTREXATE
Outcome Measures: Complete or partial LAR (lack of remission);   Mean trough level;   Sustained steroid free remission;   Presence of ATI;   Corticosteroid free remission;   Hospitalizations for LOR (loss of response) or failure to obtain remission;   Medication associated adverse events
15 Recruiting Long-Term Study of Multi-target Therapy as Continuous Induction and Maintenance Treatment for Lupus Nephritis
Condition: Lupus Nephritis
Interventions: Drug: Tacrolimus+mycophenolate mofetil;   Drug: Azathioprine
Outcome Measure: To compare the efficacy and safety of Aza
16 Recruiting ENHANCED Device Programming to Reduce Therapies and Improve Quality of Life in Implantable Cardioverter Defibrillator (ICD) Patients
Condition: Cardiac Arrhythmias
Intervention: Device: Enhanced ICD programming
Outcome Measures: Number of intervention-related safety events;   Number of ATPs/shocks;   Quality of life;   Distress
17 Recruiting Pneumococcal Vaccination of Crohn Patients
Condition: Crohns Disease
Interventions: Biological: Prevenar 13;   Biological: Pneumovax
Outcome Measures: Change in antibody titers;   Change in antibody titers as a function of Crohns disease treatment
18 Unknown  The Effect of Infliximab on Sperm Quality
Conditions: Crohn's Disease;   Ulcerative Colitis
Intervention: Other: sperm quality test
Outcome Measure:
19 Recruiting Efficacy and Safety of Two Treatment Models in Subjects With Moderate to Severe Crohn's Disease
Condition: Crohn's Disease
Interventions: Biological: adalimumab;   Drug: prednisone;   Drug: azathioprine
Outcome Measures: Rate of mucosal healing as defined by the Crohn's Disease Endoscopic Index of Severity (CDEIS) score at 48 weeks after Randomization;   Assess Pharmacokinetics (PK) of adalimumab following subcutaneous injection; a PK blood draw at protocol defined time points. Serum concentrations of adalimumab will be determined using a validated Ligand binding assay (LBA) method.;   Safety will be assessed through clinical laboratory tests, vital signs, physical exams and adverse event assessments.
20 Recruiting Weaning of Immunosuppression in Nephritis of Lupus
Condition: Nephritis of Lupus
Interventions: Drug: mycophenolate mofetil or azathioprine;   Other: immunosuppressive treatment discontinuation
Outcome Measures: discontinuation of maintenance immunosuppressive therapy;   compare 2 therapeutic strategies

These studies may lead to new treatments and are adding insight into Imuran etiology and treatment.

A major focus of Imuran research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Imuran